Biomarker Core

生物标志物核心

• 批准号: 10176347
• 负责人: TONY WYSS-CORAY
• 金额: $ 47.79万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-01 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10176347
• 关键词: Algorithmic Analysis; Alzheimer' s Disease; Alzheimer' s disease diagnosis; Alzheimer’s disease biomarker; Amyloid beta-42; Amyloid beta-Protein; Bioinformatics; Biological Assay; Biological Markers; Biology; Blood; Blood Cells; Cardiovascular Diseases; Cells; Clinical; Clinical Management; Collection; Cytometry; DNA; Data; Data Analyses; Data Set; Databases; Dementia; Detection; Development; Diabetes Mellitus; Disease; Equipment and supply inventories; Feces; Fibroblasts; Gene Expression; Genetic; Glial Fibrillary Acidic Protein; Goals; Human; Image; Immune; Individual; Information Dissemination; Lead; Light; Liquid substance; Measurement; Measures; Methods; Mission; Molecular; Nerve Degeneration; Neurodegenerative Disorders; Parkinson Disease; Parkinson' s Dementia; Participant; Pathologic Processes; Peripheral Blood Mononuclear Cell; Phenotype; Plasma; Populations at Risk; Process; Proteome; Proteomics; Publishing; Quality Control; RNA; Reproducibility; Research; Research Personnel; Sampling; Sensitivity and Specificity; Signal Transduction; Skin; Source; Standardization; T-Cell Receptor; Technology; Time; Tissues; Training Support; Work; analysis pipeline; base; bioinformatics tool; biomarker performance; data management; data sharing; experience; genetic variant; gut microbiome; imaging modality; member; microbiome; molecular marker; multiple omics; neurofilament; neuropathology; next generation; novel; novel marker; novel therapeutics; receptor expression; research study; skin microbiome; stool sample; tau Proteins; tau-1; tissue biomarkers; tool; transcriptome; transcriptome sequencing; transcriptomics; web portal; whole genome

1. SUMMARY (Biomarker Core) Biomarkers have enormous value for the detection, management, and treatment of disease, but also for the development of novel therapeutics. The utility of biomarkers is most evident in the management of cardiovascular disease and diabetes, but biomarkers, especially predictive, easily obtainable ones, are still largely absent with respect to neurodegenerative diseases. The best fluid biomarkers currently available for Alzheimer’s disease (AD) include; Aβ, tau, and neurofilament in CSF, a biofluid which is difficult to collect in healthy, at-risk populations or on a repeated basis. Other biomarkers for AD include imaging modalities which are often very expensive or have low sensitivity and specificity at the individual level. The members of this core have considerable experience in unbiased multi-omic screens and data analysis and, over the years, have published numerous studies towards developing new biomarkers for neurodegenerative and other diseases. Enabled by the current ADRC, the core leaders and collaborators have used biospecimens from Stanford ADRC participants and generated extensive preliminary data with unbiased deep immune phenotyping, proteomics, and transcriptomics of human CSF resident cells, and discovered novel Parkinson's disease (PD) biomarkers. Based on this expertise, the mission of this Biomarker Core is to facilitate the discovery of novel biomarkers for AD and PD, as well as new biology underlying the pathological processes that lead to dementia in line with the core mission of the NAPA. This will be achieved by pursuing the collection of genetic and molecular measurements from a broad source of tissues from ADRC participants; the processing and dissemination of this information in useable formats through web portals and other means (i.e., “Deep Phenotyping Database”); the analysis and bioinformatics integration of the collected information with clinical and imaging data, as well as information from public databases; and the development and dissemination of new data analysis algorithms and pipelines.

1.摘要(Biomarker Core) 生物标志物对于疾病的检测、管理和治疗具有巨大的价值，而且对于 开发新的治疗方法。生物标记物的效用在生物标记物的管理中最为明显 心血管疾病和糖尿病，但生物标记物，特别是预测的，容易获得的，仍然是 在神经退行性疾病方面基本不存在。目前最好的流体生物标记物 阿尔茨海默病(AD)包括脑脊液中的β、tau和神经丝，这是一种很难收集的生物液体 健康的、处于危险中的人群或重复使用。AD的其他生物标志物包括成像方式 往往非常昂贵，或者在个人层面上敏感性和特异性较低。这个核心的成员 在无偏见的多组筛选和数据分析方面拥有相当丰富的经验，多年来 发表了大量研究，旨在为神经退行性疾病和其他疾病开发新的生物标记物。 在当前ADRC的支持下，核心领导人和合作者使用了斯坦福大学的生物样品 ADRC参与者并生成了广泛的初步数据，这些数据具有无偏见的深度免疫表型， 蛋白质组学和人类脑脊液驻留细胞的转录组学，并发现了新的帕金森病(PD) 生物标志物。基于这些专业知识，该Biomarker Core的使命是促进发现新的 AD和PD的生物标记物以及导致痴呆的病理过程背后的新生物学 与国家适应行动方案的核心使命相一致。这将通过收集遗传和 来自ADRC参与者的广泛来源组织的分子测量；加工和 以可用格式通过门户网站和其他方式(即“深度”)传播这一信息 表型数据库“)；收集的信息与临床的分析和生物信息学集成 和成像数据以及来自公共数据库的信息；以及开发和传播 新的数据分析算法和管道。